XTX Topco Ltd Takes Position in Larimar Therapeutics, Inc. $LRMR

XTX Topco Ltd bought a new position in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 167,404 shares of the company’s stock, valued at approximately $484,000. XTX Topco Ltd owned about 0.20% of Larimar Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of LRMR. American Century Companies Inc. grew its stake in Larimar Therapeutics by 7.8% during the 2nd quarter. American Century Companies Inc. now owns 69,285 shares of the company’s stock valued at $200,000 after purchasing an additional 5,001 shares in the last quarter. Rhumbline Advisers raised its position in shares of Larimar Therapeutics by 15.7% in the 1st quarter. Rhumbline Advisers now owns 65,018 shares of the company’s stock valued at $140,000 after purchasing an additional 8,818 shares in the last quarter. Velan Capital Investment Management LP boosted its stake in shares of Larimar Therapeutics by 55.6% during the 1st quarter. Velan Capital Investment Management LP now owns 28,000 shares of the company’s stock valued at $60,000 after buying an additional 10,000 shares during the last quarter. Algert Global LLC grew its position in shares of Larimar Therapeutics by 91.0% during the first quarter. Algert Global LLC now owns 23,280 shares of the company’s stock worth $50,000 after buying an additional 11,090 shares in the last quarter. Finally, Savant Capital LLC acquired a new stake in shares of Larimar Therapeutics during the second quarter worth approximately $39,000. Institutional investors and hedge funds own 91.92% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on LRMR. Robert W. Baird cut their price target on shares of Larimar Therapeutics from $10.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Wednesday, October 8th. Wedbush cut their target price on shares of Larimar Therapeutics from $15.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 30th. JMP Securities reduced their price target on shares of Larimar Therapeutics from $22.00 to $18.00 and set a “market outperform” rating on the stock in a research report on Friday, August 15th. Finally, Oppenheimer lowered their price objective on Larimar Therapeutics from $26.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, October 2nd. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Larimar Therapeutics Price Performance

LRMR stock opened at $3.68 on Friday. The firm has a market cap of $304.63 million, a price-to-earnings ratio of -1.91 and a beta of 1.05. Larimar Therapeutics, Inc. has a 1-year low of $1.61 and a 1-year high of $6.91. The firm has a fifty day moving average price of $3.90 and a two-hundred day moving average price of $3.53.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.22). As a group, analysts expect that Larimar Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.